• Naomi Pearce, Emily Bristow

Pearce IP COVID-19 Vaccine Updates AU

  • 16 Nov 20 | CSL | CSL's Sequiris announced it will build a next-generation $800 million influenza vaccine manufacturing facility in Australia. The facility is expected to be operational by mid-2026 and will be the only cell-based influenza vaccine manufacturing facility in the Southern Hemisphere.

  • 13 Nov 20 | All | PM Scott Morrison announced the National Cabinet has endorsed a national vaccination policy. The policy focusses on five key areas; R&D, purchase and manufacturing, international partnerships, regulation and safety and immunisation administration and monitoring.

  • 08 Nov 20 | CSL, AZ, Oxford | CSL confirmed it will commence manufacturing AZD1222 (AZ/Oxford vaccine) on 09 November 2020. The product will be manufactured at its facility in Broadmeadows, Victoria, in eight large scale batches over 2020-21.

  • 05 Nov 20 | Novavax, Pfizer/BioNTech | The Australian Government announced it has secured an additional 50 million potential COVID-19 vaccine doses through agreements with Novavax and Pfizer/BioNTech.

  • 01 Nov 20 | All | SBS News reported Federal Health Minister Greg Hunt announced the Government is close to securing two supply contracts for an additional two proposed COVID-19 vaccines. Additionally, Minister Hunt announced that PM Scott Morrison will present a plan for vaccine rollout to National Cabinet in the coming weeks.

  • 31 Oct 20 | All | Minister for Foreign Affairs Marise Payne announced the Australian Government has committed an additional $500 million over the next three years to supporting access to safe and effective COVID-19 vaccines for the Pacific and Southeast Asia region. This funding is additional to the $23.2 million committed in the Budget, the Government's commitments to the COVAX facility and the existing Advance Purchase Agreements with Astra Zenexa-Oxford and CSL-University of Queensland.

  • 25 Oct 20 | All | Industry Minister Karen Andrews announced it could take up to 12 months to roll out a COVID-19 vaccine, if the successful candidate is not protein-based. Andrews explained that while CSL has a lot of experience in producing protein-based vaccines, mRNA vaccines have never been successfully manufactured and distributed.

  • 24 Oct 20 | AZ | AstraZeneca announced it has resumed clinical trials in the US following authorisation from the FDA. The trials have now fully resumed globally.

  • 07 Oct 20 | All | In its annual 2020 budget, the Australian Government acknowledged the damage to Australia's economy caused by vaccine uncertainty. The Government also pledged $23.2 million over the next three years to the COVID-19 Vaccine Access and Health Security Program to support the development of national immunisation policies in Pacific and Southeast Asian countries. A further $304.7 million has been pledged for additional recovery support for Pacific Island countries and Timor-Leste.

  • 23 Sep 20 | All | The Australian Government announced it has joined the COVAX facility, committing an initial $123.2 million for the ability to purchase vaccines when they become available. The COVAX facility is a collaboration between Gavi, the Coalition for Epidemic Preparedness Innovations, the WHO and other organisations and aims to ensure equitable access to COVID-19 vaccines.

  • 20 Sep 20 | University of Sydney, University of Melbourne | SBS News reported the Australian Government has committed $6 million to the research and development of three potential COVID-19 vaccines. The University of Melbourne will receive $3 million for the development of two vaccines, and the University of Sydney will receive $3 million to commence clinical trials of a novel DNA-based COVID-19 vaccine.

  • 12 Sep 20 | AZ | AstraZeneca announced it has resumed clinical trials in the UK and Brazil following confirmation by the Medicines Health Regulatory Authority (MHRA) that it was safe to do so.

  • 09 Sep 20 | AZ | AstraZeneca announced it has voluntarily paused Ph III trials of AZD1222 to investigate a potentially unexplained illness in one of the trials. AZ said it will expedite the review of the single event to minimise any impact to the trial timeline.

  • 06 Sep 20 | CSL | CSL announced it will supply the Australian Government with 51 million doses of UQ's vaccine candidate UQ-CSL V451 if proven successful. The first tranche of doses is expected to be available by mid-2021, with additional doses expected in late 2021 and early 2022. The vaccine candidate is currently in Ph I trials.

  • 31 Aug 20 | AZ | AstraZeneca announced it has commenced Ph III trials of AZD1222. Up to 30,000 adults in the US will be recruited, with testing sites also in Peru, Chile, UK, Brazil and South Africa. The results of the trial are anticipated later this year.

  • 19 Aug 20 | AstraZeneca | The Prime Minister's office announced the Australian Government has signed a Letter of Intent with AstraZeneca for the supply of the University of Oxford's COVID-19 vaccine candidate AZD1222. If trials prove successful, safe and effective, it is expected that every Australian will have access to the free vaccine.

  • 18 Aug 20 | CSL | CSL confirmed the development of the University of Queensland's (UQ) vaccine candidate remains its priority. CSL also disclosed that it has entered discussions with AstraZeneca and the Australian Government to assess whether it can provide local manufacturing support for the Oxford University/AZ vaccine should it prove successful.

  • 20 Jul 20 | AZ | AstraZeneca announced interim results from ongoing Ph I/II trial showed AZD1222 was tolerated and generated robust immune responses against the SARS-CoV-2 virus in all evaluated participants.

  • 13 Jul 20 | CSL | CSL announced it has commenced Ph I trials of its proposed COVID-19 vaccine. The clinical batch of vaccine for use in the trial has been manufactured by the UQ and CSIRO, with technical assistance from CSL and Cytiva.

  • 05 Jun 20 | CSL | The Coalition for Epidemic Preparedness Innovations, CSL and the University of Queensland announced they have entered into a partnering agreement to accelerate the development, manufacture and distribution of a COVID-19 vaccine candidate.

  • 30 Apr 20 | AZ | AstraZeneca and the University of Oxford announced an agreement for the global development and distribution of a potential recombinant adenovirus vaccine.

Biosimilars Bulletin 
Search by tags

© 2019 Pearce IP | Australia

  • LinkedIn Social Icon